Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting
Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study
Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…Abstract Number: 651 • 2016 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study
Background/Purpose: An increasing number of RA and PsA patients achieve low levels of disease activity under biological therapy. Thus, new biomarkers are needed to stratify…Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…Abstract Number: 653 • 2016 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Highly Expressed By Salivary Gland Epithelial Cells of Sjögren’s Syndrome Patients, Both Constitutively and upon Exposure to Necrotic Cells Debris
Background/Purpose: Sjögren’s syndrome (SS) patients manifest inflammation in salivary glands (SG) (lymphocytic infiltration of salivary and lachrymal glands) and evidence of intrinsic activation in the…Abstract Number: 654 • 2016 ACR/ARHP Annual Meeting
The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome
Background/Purpose: Primary Sjögren`s syndrome (pSS) is an autoimmune diseases characterized by lymphocytic infiltration of exocrine glands and dysregulated proliferation and differentiation of B cells. Two…Abstract Number: 655 • 2016 ACR/ARHP Annual Meeting
Comprehensive Immuno-Phenotyping of Follicular Helper T Cells and B Cell Subpopulations in Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by immune cell infiltration in the salivary glands resulting in ocular and oral dryness.…Abstract Number: 656 • 2016 ACR/ARHP Annual Meeting
ERdj5 Function Is Involved in Inflammatory Manifestations of Sjögren’s Syndrome in the Salivary Glands
Background/Purpose: Sjögren’s syndrome is a chronic autoimmune disorder that affects mainly the exocrine glands. The initiation and causative agents are still unknown. Endoplasmic Reticulum (ER)…Abstract Number: 657 • 2016 ACR/ARHP Annual Meeting
Expression of Type-III Interferons (IFNλs) and Their Receptor in Sjögren’s Syndrome
Background/Purpose: Type-III IFNs or IFNλs(IFNλ1/IL29, IFNλ2/IL28A and IFNλ3/IL28B) consist a recently identified group of IFNs,initiallyimplicated inseveral human diseases, including cancer and autoimmunity. In this study,…Abstract Number: 658 • 2016 ACR/ARHP Annual Meeting
Decreased Expression of Ten Micro-RNAs in Plasmacytoid Dendritic Cells of Patients with Primary SS Indicates Dysregulation on Multiple Levels
Background/Purpose: Plasmacytoid dendritic cells (pDCs) are indicated to be key players in the pathogenesis of primary Sjögren’s syndrome (pSS) and important producers of type-1 interferon…Abstract Number: 659 • 2016 ACR/ARHP Annual Meeting
Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome
Background/Purpose: The therapy for sjogren’s syndrome (SS) focuses on biological agents, immune inhibitors and glucocorticoid which can’t correct the problem of unbalance of Th17 and…Abstract Number: 660 • 2016 ACR/ARHP Annual Meeting
Expression of the Chemokine Receptor CXCR5 Is Decreased in the Periphery of Patients with Primary Sjogren’s Syndrome
Background/Purpose: CXCR5 is a chemokine receptor expressed on B and T cell subsets, which binds the CXCL13 ligand produced by follicular dendritic cells. It is…Abstract Number: 661 • 2016 ACR/ARHP Annual Meeting
Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
Background/Purpose: Circulating autoantibodies reactive against Ro52 are detected in the sera of 70% of patients with Sjögren’s syndrome (SS), and their presence has been associated…Abstract Number: 662 • 2016 ACR/ARHP Annual Meeting
The Unusual Cross-Reactivity of Anti Muscarinic Receptor 3 Monclonal Antibodies Derived from Salivary Glands of Sjögren’s Syndrome Patients to Ro Peptides
Background/Purpose: Sjogrens syndrome (SS) is a chronic autoimmune inflammatory disease the characterisitic features of which includes hypofunction of exocrine glands leading to decrease in salivation…Abstract Number: 663 • 2016 ACR/ARHP Annual Meeting
Cytokine and Chemokine Levels in Serum and Tears As Disease Activity Biomarkers in Patients with Primary Sjögren´s Syndrome
Background/Purpose: Evidence suggests that levels of different cytokines in primary Sjögren´s syndrome (pSS) are associated with cell infiltration degree within lacrimal and salivary glands and…
ACR Meeting Abstracts